Precigen (PGEN) surged dramatically since the FDA approval of PAPZIMEOS, its first-in-class therapy for Recurrent Respiratory Papillomatosis (RRP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results